Seagen

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
Seagen, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Seagen please access Flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Seagen, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medical Wei (Shenzhen) Biotechnology Co., Ltd. ("Medicovestor"), wholly owned by MEDICOVESTOR SDN BHD, announced the completion of a seed financing round of several million RMB, led by Tongmengzhe (Shenzhen) Pharmaceutical…

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy

CompanyDrug

Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer

CompanyDrug

Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer

CompanyDeals

Gracell Secures Non-Exclusive License for Cell Therapies from Seagen

CompanyDrug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

CompanyDrug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

CompanyDeals

Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization

Show More